Research: •Samuel Benjamin Schottler •Michael D. Mosher Advisor: Matthew DeSelm
references: •Norman, A. L., Shurrush, K. A., Calleroz, A. T., & Mosher, M. D. (2007, July 23). A tandem oximation-cyclization route to ∆2-isoxazolines. •Norman, A. L., Mosher, M. D. (2008, April 22). Enantioselectivity in the synthesis of 3,5-disubstituted ∆2-isoxazolines. •Khoufache, K., Bazin, S., Girard, K., et al. (2012, April 19). Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo. •Asare, Y., Schmitt, M., & Bernhagen, J. (2012, December 3). The vascular biology of macrophage migration inhibitory factor (MIF): Expression and effects in inflammation, atherogenesis and angiogenesis •Conroy, H., Mawhinney, L., & Donnelly, S. C. (2010, August 30). Inflamation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link. •Toso, C., Emamaulle, J. A., Merani, S., Shapiro, A. M. J. (2008, May 12). The role of macrophage inhibitory factor on glucose metabolism and diabetes. •Stojanović, I., Maksimović, D., Al-Abed, Y., et al. (2008). Control of the final stage of immune-mediated diabetes by ISO-1, and antagonist of macrophage migration inhibitory factor . •Al-Abed, Y., VanPatten, S. (2011). MIF as a disease target: ISO-1 as a proof-of-concept therapeutic.